COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity

COVIDView Summary ending on September 5, 2020

COVIDView Summary ending on September 5, 2020
Updated Sept. 11, 2020

Download Weekly Summary pdf icon[13 Pages, 1.4 MB]

Key Updates for Week 36, ending September 5, 2020

After declining since mid-July, the percentage of laboratory specimens testing positive for SARS-CoV-2 nationally increased slightly during week 35 but then decreased during week 36. Indicators that track influenza-like illness (ILI) and COVID-19-like illness (CLI) continued to decrease or remain stable (change of ≤0.1%) nationally and in all 10 regions; however, due to COVID-19 activity, one region reported levels of ILI above the region-specific baseline. Weekly hospitalization rates and mortality attributed to COVID-19 declined during week 36. Mortality attributed to COVID-19 remains above the epidemic threshold.

Virus

Public Health, Commercial and Clinical Laboratories

Nationally, the percentage of respiratory specimens testing positive for SARS-CoV-2 decreased from 5.5% during week 35 to 5.1% during week 36. National percentages of specimens testing positive for SARS-CoV-2 by type of laboratory are listed as follows:

  • Public health laboratories – decreased from 6.2% during week 35 to 5.4% during week 36;
  • Clinical laboratories – decreased from 5.4% during week 35 to 4.5% during week 36;
  • Commercial laboratories – decreased from 5.5% during week 35 to 5.1% during week 36.

Outpatient and Emergency Department Visits

Outpatient Influenza-Like Illness Network (ILINet) and National Syndromic Surveillance Program (NSSP)

Two surveillance networks are being used to track outpatient or emergency department (ED) visits for illness with symptoms compatible with COVID-19.

  • Nationally, ILI activity remains below baseline for the 21st consecutive week and is at levels that are typicalfor this time of year.
  • Nationally, the percentage of visits reported for ILI by ILINet participants decreased from 1.0% during week 35 to 0.9% during week 36. The percentage of visits for CLI reported to NSSP decreased for the eighth consecutive week, from 2.1% during week 35 to 1.8% during week 36.
  • Recent changes in health care seeking behavior, including increasing use of telemedicine, recommendations to limit ED visits to severe illnesses, and increased social distancing, are likely affecting both networks, making it difficult to draw conclusions at this time. Tracking these systems moving forward will give additional insight into illness related to COVID-19.

Severe Disease

Hospitalizations

Cumulative COVID-19-associated hospitalization rates since March 1, 2020, are updated weekly. The overall cumulative COVID-19 hospitalization rate is 166.9 per 100,000, with the highest rates in people aged 65 years and older (451.2 per 100,000) and 50–64 years (249.8 per 100,000).

Mortality

Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 36 is 6.3%. This is currently lower than the percentage during week 35 (9.5%); however, the percentage remains above the epidemic threshold and will likely increase as more death certificates are processed.

All data are preliminary and may change as more reports are received.

A description of the surveillance systems summarized in COVIDView, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.

Key Points

  • Nationally, since mid-July, there has been an overall decreasing trend in the percentage of specimens testing positive for SARS-CoV-2 and a decreasing or stable (change of ≤0.1%) trend in the percentage of visits for ILI and CLI; however, there has been some regional variation.
  • Using combined data from the three laboratory types, the national percentage of respiratory specimens testing positive for SARS-CoV-2 with a molecular assay decreased from 5.8% during week 35 to 5.2% during week 36.
    • Regionally, the percentage of respiratory specimens testing positive for SARS-CoV-2 increased slightly in Regions 1 (New England) and 3 (Mid-Atlantic) and decreased or remained stable in the remaining seven regions.
    • The highest percentages of specimens testing positive for SARS-CoV-2 were seen in Regions 4 (South East, 8.1%), 6 (South Central, 9.3%), and 7 (Central, 9.5%), but the percentage is decreasing in all three regions.
  • The percentage of outpatient or ED visits to ILINet providers for ILI is below baseline nationally and in nine of the 10 regions of the country. Region 7 (Central) reported ILI above the region-specific baseline. This increase is due to visits for ILI associated with COVID-19 activity in Iowa, which resulted in Iowa experiencing “very high” ILI activity.
    • Compared with week 35, the percentage of visits for ILI during week 36 decreased nationally and decreased or was stable (change of ≤0.1%) in all 10 regions.
  • The percentage of visits to EDs for CLI decreased nationally for the eighth consecutive week and, compared with the previous week, decreased in all 10 HHS regions. The percentage of visits to EDs for ILI was stable (change of ≤0.1%) nationally and decreasing or stable in all 10 regions.
  • The overall cumulative COVID-19-associated hospitalization rate was 166.9 per 100,000; rates were highest in people 65 years of age and older (451.2 per 100,000) followed by people 50–64 years (249.8 per 100,000).
    • Although SARS-CoV-2 viruses have been circulating in the U.S. for slightly longer than a typical influenza season, the cumulative hospitalization rate for COVID-19 among adults 65 years and older is now higher than the end-of-season influenza hospitalization rates for recent influenza seasons, including the high severity 2017­–2018 season. Since early in the pandemic, cumulative COVID-19 hospitalization rates for younger adult age groups (18-49 year olds and 50-64 year olds) have been higher than recent end-of-season hospitalization rates for influenza.
    • From the week ending August 1 (week 31) to the week ending August 29 (week 35), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates initially remained constant for children in the 5–17 year age group and then increased during the week ending August 29 (week 35). Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.
    • Hispanic or Latino persons and Non-Hispanic Black persons had age-adjusted hospitalization rates approximately 4.7 times that of non-Hispanic White persons. The rate for non-Hispanic American Indian or Alaska Native persons was approximately 4.6 times the rate among non-Hispanic White persons.
  • Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 36 was 6.3%, lower than the percentage during week 35 (9.5%), but above the epidemic threshold. These percentages will likely increase as more death certificates are processed.
  • All surveillance systems aim to provide the most complete data available. Estimates from previous weeks are subject to change as data are updated with the most complete data available.

U.S. Virologic Surveillance

The number of specimens tested for SARS-CoV-2 using a molecular assay and reported to CDC by public health laboratories and a subset of clinical and commercial laboratories in the United States are summarized below. All laboratories are performing primary diagnostic functions; therefore, the percentage of specimens testing positive across laboratory types can be used to monitor overall trends in COVID-19 activity. As the outbreak progresses, it is possible that different types of laboratories will take on different roles, and the data interpretation may need to change.

Summary of Laboratory Testing Results Reported to CDC
Summary of Laboratory Testing Results Reported to CDC* Week 36
(Aug. 30–Sept. 5, 2020)
Cumulative since March 1, 2020
No. of specimens tested 1,949,226 46,481,561
          Public Health Laboratories 261,282 5,545,867
          Clinical Laboratories 121,654 5,143,112
          Commercial Laboratories 1,566,290 35,792,582
No. of positive specimens (%) 99,799 (5.1%) 3,934,090 (8.5%)
          Public Health Laboratories 14,238 (5.4%) 435,007 (7.8%)
          Clinical Laboratories 5,494 (4.5%) 316,682 (6.2%)
          Commercial Laboratories 80,067 (5.1%) 3,182,401 (8.9%)

* Commercial and clinical laboratory data represent select laboratories and do not capture all tests performed in the United States.

Public Health Laboratories

View Data Table

Clinical Laboratories

View Data Table

Commercial Laboratories

* Commercial laboratories began testing for SARS-CoV-2 in early March, but the number and geographic distribution of reporting commercial laboratories became stable enough to calculate a weekly percentage of specimens testing positive as of March 29, 2020.

View Data Table

Additional virologic surveillance information: Surveillance Methods

Outpatient/Emergency Department Illness

Two syndromic surveillance systems are being used to monitor trends in outpatient and emergency department (ED) visits that may be associated with COVID-19 illness. Each system monitors a slightly different syndrome, and together, these systems provide a more comprehensive picture of mild-to-moderate COVID-19 illness than either would individually. Both systems are currently being affected by changes in health care seeking behavior, including increased use of telemedicine, compliance with recommendations to limit ED visits to severe illnesses, and increased social distancing. These changes affect the numbers of people seeking care in the outpatient and ED settings and their reasons for doing so.

ILINet

The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) provides data on visits for influenza-like illness (ILI) (fever [≥100F] and cough and/or sore throat) to approximately 2,600 primary care providers, emergency departments, and urgent care centers in all 50 states, Puerto Rico, the District of Columbia, and the U.S. Virgin Islands. Mild COVID-19 illness presents with symptoms similar to ILI, so ILINet is being used to track trends of mild-to-moderate COVID-19 illness and allows for comparison with prior influenza seasons.

Nationwide during week 36, 0.9% of patient visits reported through ILINet were due to ILI. This percentage is well below the national baseline of 2.4% and is typical for this time of year compared to previous influenza seasons. Compared with week 35, the percentage of visits for ILI during week 36 was the same or lower overall and among all age groups.

* Age-group specific percentages should not be compared with the national baseline.

On a regional levelexternal icon, the percentage of outpatient visits for ILI ranged from 0.4% to 2.1% during week 36. Compared with week 35 the percentage was declining or stable (changes of ≤0.1%) in all ten regions. The percentage of outpatient visits for ILI was below the region-specific baseline in nine regions; however, Region 7 (Central) reported ILI above the region-specific baseline for the past two weeks. This increase is due to increased ILI activity in Iowa and is associated with COVID-19 activity.

Note: In response to the COVID-19 pandemic, new data sources are being incorporated into ILINet through the summer weeks, when lower levels of influenza and other respiratory virus circulation are typical. Starting in week 21, enrollment of new sites began, leading to increases in the number of patient visits. While all regions remain below baseline levels for ILI, these system changes should be considered when drawing conclusions from these data. Any changes in ILI due to changes in respiratory virus circulation will be highlighted here.

Overall Percentage of Visits for ILI | Age Group ILI Data

ILI Activity Levels

Data collected in ILINet are used to produce a measure of ILI activity for all 50 states, Puerto Rico, the U.S. Virgin Islands, the District of Columbia, and New York City. The mean reported percentage of visits due to ILI for the current week is compared with the mean reported during non-influenza weeks, and the activity levels correspond to the number of standard deviations below, at, or above the mean.

The number of jurisdictions at each activity level during week 36 and changes compared with the previous week are summarized in the table below and shown in the following maps.

ILI Activity Levels
Activity Level Number of Jurisdictions
Week 36
(Week ending
September 5, 2020)
Compared with Previous Week
Very High 1 +1
High 0 No change
Moderate 0 No change
Low 1 No change
Minimal 50 -1
Insufficient Data 2 No change

*Data collected in ILINet may disproportionally represent certain populations within a state and may not accurately depict the full picture of influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

National Syndromic Surveillance Program (NSSP): Emergency Department (ED) Visits

NSSP is a collaboration among CDC, federal partners, local, and state health departments and academic and private sector partners to collect, analyze, and share electronic patient encounter data received from multiple health care settings. To track trends of potential COVID-19 visits, visits for COVID-19-like illness (CLI) (fever and cough or shortness of breath or difficulty breathing or presence of a coronavirus diagnosis code) and ILI to a subset of emergency departments in 47 states are being monitored.

Nationwide during week 36, 1.8% of ED visits captured in NSSP were due to CLI and 0.7% were due to ILI. Compared with week 35, this week the percentage of visits for CLI and the percentage of visits for ILI decreased or remained stable (changes of ≤0.1%) nationally and in all 10 HHS regionsexternal icon.

Additional information about medically attended outpatient and emergency department visits for ILI and CLI: Surveillance Methods

Hospitalizations

The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in select counties participating in the Emerging Infections Program (EIP) and the Influenza Hospitalization Surveillance Project (IHSP).

A total of 54,425 laboratory-confirmed COVID-19-associated hospitalizations were reported by sites between March 1, 2020 and September 5, 2020. The overall cumulative hospitalization rate was 166.9 per 100,000 population. Among the 0–4 year, 5–17 year, 18–49 year, 50–64 year, and ≥65 year age groups, the highest rate of hospitalization was among adults aged ≥65 years, followed by adults aged 50–64 years and adults aged 18–49 years.

Hospitalization Rates
Age Group Cumulative Rate per 100,000 Population
Overall 166.9
     0-4 years 16.8
     5-17 years 9.7
     18-49 years 113.8

  18-29 years

72.5

  30-39 years

113.4

  40-49 years

167.5
    50-64 years 249.8
    65+ years 451.2

  65-74 years

338.9

  75-84 years

534.9

  85+ years

814.6

Weekly hospitalization rates among all ages first peaked during the week ending April 18 (MMWR week 16), followed by a second peak during the week ending July 18 (MMWR week 29). From the week ending August 1 (MMWR week 31) to the week ending August 29 (MMWR week 35), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates initially remained constant in the 5–17 year age group and increased during the week ending August 29 (MMWR week 35). Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.

Among the 54,425 laboratory-confirmed COVID-19-associated hospitalizations, 51,286 (94.2%) had information on race and ethnicity; collection of race and ethnicity was still pending for 3,139 (5.8%) hospitalizations. When examining overall age-adjusted rates by race/ethnicity, both Hispanic or Latino persons and non-Hispanic Black persons had age-adjusted hospitalization rates approximately 4.7 times that of non-Hispanic White persons. The rate for non-Hispanic American Indian or Alaska Native persons was approximately 4.6 times the rate among non-Hispanic White persons.

When examining age-stratified crude hospitalization rates by race and ethnicity, compared with non-Hispanic White persons in the same age group, crude hospitalization rates were 8.0 times higher among Hispanic or Latino persons aged 0–17 years; 8.6 times higher among Hispanic or Latino persons aged 18–49 years; 6.2 times higher among non-Hispanic American Indian or Alaska Native persons aged 50–64 years; and 3.8 times higher among non-Hispanic Black persons aged ≥65 years.

Hospitalization rates per 100,000 population
by age and race and ethnicity — COVID-NET,
March 1, 2020–September 5, 2020

Age Category

Non-Hispanic
American Indian or Alaska Native

Non-Hispanic Black

Hispanic or Latino

Non-Hispanic Asian or Pacific Islander

Non-Hispanic White

Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3
0—17 years 13.6 4.7 17.2 5.9 22.3 8.0 6.0 2.1 2.9 1
18—49 years 247.8 8.0 184.3 5.9 265.6 8.6 53.1 1.7 31.0 1
50—64 years 603.5 6.2 513.6 5.3 570.0 5.8 156.0 1.6 97.7 1
65+ years 685.5 2.5 1028.8 3.8 743.4 2.7 293.7 1.1 273.6 1
Overall rate4 (age-adjusted) 332.3 4.6 339.0 4.7 341.1 4.7 97.7 1.3 72.8 1

1 COVID-19-associated hospitalization rates by race/ethnicity are calculated using COVID-NET hospitalizations with known race and ethnicity for the numerator and NCHS bridged-race population estimates for the denominator.
2 For each age category, rate ratios are the ratios between crude hospitalization rates within each racial/ethnic group and the crude hospitalization rate among non-Hispanic white persons in the same age category.
3 The highest rate ratio in each age category is presented in bold.
4 Overall rates are adjusted to account for differences in age distributions within race/ethnicity strata in the COVID-NET catchment area; the age strata used for the adjustment include 0-17, 18-49, 50-64, and 65+ years.

Non-Hispanic Black persons and non-Hispanic White persons represented the highest proportions of hospitalizations reported to COVID-NET, followed by Hispanic or Latino, non-Hispanic Asian or Pacific Islander, and non-Hispanic American Indian or Alaska Native persons. However, some racial and ethnic groups are disproportionately represented among hospitalizations as compared with the overall population of the catchment area. Prevalence ratios were highest among non-Hispanic American Indian or Alaska Native persons, followed by non-Hispanic Black persons and Hispanic or Latino persons.

Comparison of proportions of COVID-19-associated hospitalizations by race and ethnicity, COVID-NET, March 1–September 5, 2020
Non-Hispanic American Indian or Alaska Native Non-Hispanic Black Hispanic or Latino Non-Hispanic Asian or Pacific Islander Non-Hispanic White
Proportion of hospitalized COVID-NET cases1 1.3% 33.0% 23.1% 5.0% 31.5%
Proportion of population in COVID-NET catchment 0.7% 17.9% 14.1% 8.9% 58.5%
Prevalence ratios2 1.9 1.8 1.6 0.6 0.5

1 Persons of multiple races (0.3%) or unknown race and ethnicity (5.8%) are not represented in the table but are included as part of the denominator.
2 Prevalence ratio is calculated as the ratio of the proportion of COVID-NET hospitalizations over the proportion of population in COVID-NET catchment area.

Among 10,824 hospitalized adults with information on underlying medical conditions, 90.3% had at least one reported underlying medical condition. The most commonly reported underlying medical conditions were hypertension, obesity, metabolic disease, and cardiovascular disease. Among 344 hospitalized children with information on underlying conditions, 50.3% had at least one reported underlying medical condition. The most commonly reported underlying medical conditions were obesity, neurologic disease, and asthma.

Additional data on demographics, signs and symptoms at admission, underlying conditions, interventions, outcomes and discharge diagnoses, stratified by age, sex and race and ethnicity, are available.

Additional hospitalization surveillance information: Surveillance Methods  | Additional rate data  |  Additional demographic and clinical data

Mortality Surveillance

The National Center for Health Statistics (NCHS) collects death certificate data from vital statistics offices for all deaths occurring in the United States. Based on death certificate data available on September 10, 2020, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 36 is 6.3% and, while lower than the percentage during week 35 (9.5%), remains above the epidemic threshold. Percentages for recent weeks will likely increase as more death certificates are processed.

Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates. Percentages of deaths due to PIC are higher among manually coded records than more rapidly available machine coded records. Due to the additional time needed for manual coding, the initially reported PIC percentages may be lower than percentages calculated from final data.

*Data during recent weeks are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes.

View Data Table

Additional NCHS mortality surveillance information: Surveillance Methods  | Provisional Death Counts for COVID-19